Clinical Characteristics of Dialysis Related Sclerosing Encapsulating Peritonitis: Multi-center Experience in Korea

Sclerosing encapsulating peritonitis (SEP) is a rare but serious complication in patients with continuous ambulatory peritoneal dialysis (CAPD), and is characterized by a progressive, intra-abdominal, inflammatory process resulting in the formation of sheets of new fibrous tissue, which cover, bind, and constrict the viscera, thereby compromising the motility of the bowel. No satisfactory estimate is available on the comparative incidence of dialysis related SEP and the pathogenesis of SEP still remains uncertain. Although recent therapeutic approaches have reported varying degrees of success, an efficient measure to detect, at an early stage, patients at risk for SEP would be beneficial and a standardized treatment regimen to prevent the illness is urgently needed. This study aimed to evaluate the clinical features of SEP and to identify the possible risk factors for the development of SEP in CAPD patients. We retrospectively reviewed by questionnaire SEP cases among CAPD patients from 7 university hospital dialysis centers in Korea, including Yonsei University, Ajou University, Catholic University, Inha University, Kyungpook University, Seoul National University and Soonchunhyang University, from January 1981 to December 2002. Out of a total of 4,290 CAPD patients in these centers, 34 cases developed SEP with an overall prevalence of 0.79%. The male to female ratio was 17:17. The median age of these patients was 44.5 years (range 19 - 66). The median duration of CAPD before SEP was 64 months (9 - 144) and 68% of patients (23/34) had been on CAPD for more than 4 years. Peritonitis (including two fungal cases) was the main cause of catheter removal in SEP (27 cases, 79%). Seventy-five percent of the cases (15/20) were administered β-blocker for a mean duration of 85 months (26 - 130). Among 10 cases with available peritoneal equilibration test (PET) data, 8 showed high transporter characteristics, and the remaining 2 were high average. Eighteen cases were diagnosed by clinical and radiologic methods, and 16 were surgically diagnosed. Eleven cases were surgically treated and the others were treated conservatively with intermittent total parenteral nutrition (TPN). The overall mortality rate was 24%. SEP is a serious, life threatening complication of CAPD. Most cases had a PD duration of more than 4 years, a history of severe peritonitis, and high transporter characteristics in PET. Therefore, to reduce the incidence of SEP, careful monitoring and treatment, including early catheter removal in patients with severe peritonitis, should be considered for long-term CAPD patients with the above characteristics.

[1]  B. Wechsler,et al.  Demonstration of efficacy of combining corticosteroids and colchicine in two patients with idiopathic sclerosing mesenteritis , 1996, Digestive Diseases and Sciences.

[2]  N. Di Paolo,et al.  Peritoneal Sclerosis: One or Two Nosological Entities? , 2000, Seminars in dialysis.

[3]  S. Mujais,et al.  Encapsulating Peritoneal Sclerosis: Definition, Etiology, Diagnosis, and Treatment , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[4]  S. Mujais,et al.  Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[5]  G. Garosi,et al.  Peritoneal sclerosis. , 1999, Journal of nephrology.

[6]  S. Msika,et al.  Sclerosing Encapsulating Peritonitis: Early and Late Results of Surgical Management in 32 Cases , 1998, Digestive Surgery.

[7]  J. Bargman,et al.  Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center's experience and review of the literature. , 1998, Advances in renal replacement therapy.

[8]  R. Krediet Advances in Peritoneal Dialysis: Towards Improved Efficacy and Safety , 1998, Blood Purification.

[9]  C. Hawley,et al.  Sclerosing peritonitis: the experience in Australia. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  A. Clarkson,et al.  Relapsing CAPD peritonitis with rapid peritoneal sclerosis due to Haemophilus influenzae. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Y. Kawaguchi,et al.  Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  A. Tzamaloukas Peritonitis in peritoneal dialysis patients: an overview. , 1996, Advances in renal replacement therapy.

[13]  R. Selgas,et al.  Preserving the Peritoneal Dialysis Membrane in Long‐Term Peritoneal Dialysis Patients , 1995 .

[14]  U. Frei,et al.  Peritoneal dialysis fluid biocompatibility: does it really matter? , 1994, Kidney international. Supplement.

[15]  Marcus R. Wigan,et al.  Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  K. Nolph,et al.  Reproducibility of the peritoneal equilibration test in CAPD patients. , 1994, ASAIO journal.

[17]  M. Schein,et al.  Problems in the surgical management of sclerosing encapsulating peritonitis. , 1993, Israel journal of medical sciences.

[18]  M. Ma,et al.  Immunosuppression in sclerosing peritonitis. , 1993, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[19]  M. Mcmillan,et al.  Immunosuppression in sclerosing peritonitis. , 1993, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[20]  S. Cox,et al.  Sclerosing peritonitis with gross peritoneal calcification: a case report. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  J. Dobbie Pathogenesis of Peritoneal Fibrosing Syndromes (Sclerosing Peritonitis) in Peritoneal Dialysis , 1992, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[22]  S. Gouge,et al.  Chemical peritonitis secondary to intraperitoneal vancomycin. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  G. W. Smith,et al.  Surgical aspects of sclerosing encapsulating peritonitis. , 1990, Archives of surgery.

[24]  P. Holland Sclerosing encapsulating peritonitis in chronic ambulatory peritoneal dialysis. , 1990, Clinical radiology.

[25]  Z. Twardowski Clinical value of standardized equilibration tests in CAPD patients. , 1989, Blood purification.

[26]  F. Brunner,et al.  Case-control study to determine the cause of sclerosing peritoneal disease. , 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  A. Slingeneyer Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis. , 1987, Contributions to nephrology.

[28]  P. Brignon,et al.  Progressive calcifying peritonitis: a new complication of CAPD? Report of two cases. , 1987, Nephron.

[29]  R. Soler,et al.  Retractile mesenteritis involving the colon: barium enema, sonographic, and CT findings. , 1986, AJR. American journal of roentgenology.

[30]  R. Freeman,et al.  Peritoneal dialysis complicated by fungal peritonitis and peritoneal fibrosis. , 1984, The American journal of medicine.

[31]  J. Daugirdas,et al.  Peritoneal sclerosis in peritoneal dialysis patients. , 1984, American journal of nephrology.

[32]  D. Oreopoulos,et al.  SCLEROSING OBSTRUCTIVE PERITONITIS AFTER CAPD , 1983, The Lancet.

[33]  N. Mittman,et al.  Rhodotorula rubra peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. , 1983, American Journal of Medicine.

[34]  R. Pounder,et al.  Propranolol, oxprenolol, and sclerosing peritonitis. , 1982, British medical journal.

[35]  C. Verger,et al.  Structural and ultrastructural peritoneal membrane changes and permeability alterations during continuous ambulatory peritoneal dialysis. , 1981, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[36]  A. Leppäniemi,et al.  Peritoneal fibrosis due to practolol. Scanning electron microscopical and histological observations. , 1981, Acta chirurgica Scandinavica.

[37]  W. Geis,et al.  Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. , 1980, Archives of internal medicine.

[38]  D. Rutty,et al.  Sclerosing peritonitis with short-term propranolol therapy. , 1980, Archives of internal medicine.

[39]  B. Jackson Surgical treatment of sclerosing peritonitis caused by practolol , 1977, The British journal of surgery.

[40]  H. Baddeley,et al.  Sclerosing peritonitis due to practolol: A report on 9 cases and their surgical management , 1977, The British journal of surgery.

[41]  G. H. Hall,et al.  Letter: Intra-articular methotrexate. , 1975, Lancet.

[42]  M. Baron Structure of the intestinal peritoneum in man , 1941 .